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The non-enzymatic reaction between reducing sugars
and long-lived proteins in vivo results in the formation
of glycation and advanced glycation end products,
which alter the properties of proteins including charge,
helicity, and their tendency to aggregate. Such protein
modifications are linked with various pathologies asso-
ciated with the general aging process such as Alzheimer
disease and the long-term complications of diabetes. Al-
though it has been suggested that glycation and ad-
vanced glycation end products altered protein structure
and helicity, little structural data and information cur-
rently exist on whether or not glycation does indeed
influence or change local protein secondary structure.
We have addressed this problem using a model helical
peptide system containing a di-lysine motif derived
from human serum albumin. We have shown that, in the
presence of 50 mM glucose and at 37 °C, one of the lysine
residues in the di-lysine motif within this peptide is
preferentially glycated. Using NMR analysis, we have
confirmed that the synthetic peptide constituting this
helix does indeed form a -helix in solution in the pres-
ence of 30% trifluoroethanol. Glycation of the model
peptide resulted in the distortion of the -helix, forcing
the region of the helix around the site of glycation to
adopt a 310 helical structure. This is the first reported
evidence that glycation can influence or change local
protein secondary structure. The implications and bio-
logical significance of such structural changes on pro-
tein function are discussed.
Non-enzymatic glycation describes the initial products aris-
ing from the formation of Maillard reaction adducts due to the
reaction between primary amino groups on a protein surface
and reducing sugars such as glucose and fructose (1–4). These
non-enzymatic reactions are initiated with the reversible for-
mation of a Schiff base adduct that undergoes rearrangement
to form a more stable Amadori product (for glucose) (5) or
Heyns product (for fructose) (6). The Amadori compound may
then undergo a series of poorly understood rearrangements and
reactions to yield protein adducts collectively termed advanced
glycation end products (AGEs)1 (4). AGEs are naturally formed
in vivo on a variety of proteins and are implicated in the
pathologies associated with aging, atherosclerosis, Alzheimer
disease, and long-term diabetic complications (7). More re-
cently, glycation has been shown at the N terminus of the
pathogenic prion protein in transmissible spongiform enceph-
alopathies, a group of transmissible neurodegenerative dis-
eases that are characterized by the accumulation of abnormally
folded prion protein (8), and has been implicated in food
allergies (9).
The association of AGEs with a variety of pathologies has
resulted in much scientific interest in the role played by glyca-
tion products and AGEs in the pathology of these disease
states. For example, in recent years, the receptor for advanced
glycation end products has been described and it has since been
reported to be a member of the immunoglobulin superfamily of
cell surface proteins (10). The expression of receptor for ad-
vanced glycation end products has also been implicated as a
developmental factor in several pathologic conditions including
chronic inflammation, cancer, and Alzheimer disease (10). Fur-
thermore, a number of AGE products and cross-links have now
been described (11); however, despite much attention, the exact
role that these modified protein forms play in the associated
disease states remains to be fully elucidated.
The process of glycation and the formation of AGEs are
known to promote protein aggregation and insolubilization
(12). Furthermore, protein glycation and the formation of sub-
sequent AGE products are thought to be involved in structural
and functional changes in vivo in proteins during aging and the
long-term complications of diabetes (12, 13). Although glyca-
tion has been shown to inactivate a number of enzymes (12),
little information, if any, currently exists regarding the effects
these modifications have on protein secondary or tertiary struc-
ture. This is largely due to the problem of obtaining sufficient
homogeneous material for structural studies, because glycation
usually occurs at one or more residues on a protein structure
and gives rise to multiple AGEs.
Notwithstanding these apparent problems, Blakytny et al.
(12) used mass spectrometry and NMR to study the effect of
glycation with galactose on the C-terminal extension of -crys-
tallin, investigating both the intact protein and a synthetic
C-terminal peptide (12). Although these studies categorically
identified the sites and level of glycation, both the intact pro-
tein and synthetic peptide exhibited great conformational free-
dom and adopted no preferred structure in solution and there-
fore no conclusions could be drawn regarding the effect of
glycation on the secondary and tertiary structure of -crystal-
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lin (12). NMR has also been used recently to detect the presence
of glycated protein in the saliva of patients with diabetes (14),
whereas others (15) have used it to study the effect of glycation
on a tetrapeptide and its N-terminal amide bond stereochem-
istry and tautomeric distribution.
Despite these studies, little information currently exists on
whether or not glycation does indeed influence or change local
protein secondary structure. A previous study (16) on human
serum albumin suggests that glycation does indeed result in
conformation change, although the nature of this change was
undetermined. Others (11) have reported that glycation and
AGE product formation alter the helicity of proteins. In the
present study, we have addressed this problem using a model
peptide system derived from human serum albumin (HSA).
Human serum albumin (ExPASy primary accession number
P02768) is a helical protein that is the main protein constituent
of plasma. Although the exact function of HSA is unknown, its
primary function is thought to be to regulate the colloidal osmotic
pressure of blood (17). The primary site of glycation in human
albumin, both in vitro and in vivo, is known to be Lys525 (16).
However, several other lysine residues in albumin are known to
be glycated both in vitro and in vivo, including Lys548 as shown in
a study of bovine albumin (18). Furthermore, the lysine residue,
Lys548, resides in the same helix and in the same peptide motif in
both human and bovine serum albumin. Lys548 is of particular
interest, because it lies in a di-lysine motif (Lys548-Lys549) that is
part of a helix on the surface of the molecule (helix 28), which is
held in place relative to the rest of the molecule via a salt bridge.
Furthermore, glycation is thought to be accelerated at di-lysine
motifs due to local acid-base catalysis.
Therefore, the model peptide used in this study corresponds
to helix 28 of HSA, corresponding to residue numbers 543–557
in accordance with Swiss-Prot numbering. We have shown
that, in the presence of glucose, one of the lysine residues in the
di-lysine motif (Lys548-Lys549) within this peptide is preferen-
tially glycated. As in the intact protein, the lysine equating to
Lys548 was preferentially glycated in the model peptide system.
Furthermore, using NMR analysis, we have confirmed that the
synthetic peptide constituting this helix (residues 543–557)
does indeed form a -helix in solution in the presence of 30%
trifluoroethanol (TFE). Glycation of the model peptide resulted
in the distortion of the -helix, forcing the region of the helix
around the site of glycation to adopt a 310 helical structure.
This is the first reported evidence that glycation can indeed
influence or change local protein secondary structure. The im-
plications for such changes on protein function are discussed.
EXPERIMENTAL PROCEDURES
Materials—All of the materials were of analytical reagent grade or
better and were purchased from Sigma unless otherwise stated.
Synthesis and Purification of Peptide HSA543–557—The peptide
RERQIKKQTALVELV was synthesized with an acetylated N-terminal
amino group using a Shimadzu PSSM-8 multiple peptide synthesizer
and an Fmoc (N-(9-fluorenyl)methoxycarbonyl)/HBTu (O-(1H-benzo-
triazole-1-yl)-N,N,N,N-tetramethyluronium tetrafluoroborate) syn-
thesis strategy. The resulting peptide was then purified by reverse
phase HPLC using a preparative C18 10  250 mm column linked to a
Hewlett Packard 1100 series HPLC. The sample to be analyzed was
injected onto the column, and salts were washed out with an isocratic
gradient of 2% acetonitrile containing 0.05% trifluoroacetic acid. The
peptide was then eluted from the column using a linear gradient from
2 to 40% acetonitrile (containing 0.045% trifluoroacetic acid) over 50
min. The peptide peak was collected and then freeze-dried overnight.
Multiple runs were combined to purify all of the synthesized peptide.
The authenticity of the purified peptide was then confirmed by mass
spectrometry. Mass spectra were recorded in the positive ion mode
using the extended mass range (m/z 250–4000) on a Finnigan MAT
LCQ ion-trap mass spectrometer.
Generation and Isolation of Glycated Peptide HSA543–557—To gen-
erate glycated peptide, the peptide was dissolved in sterile PBS con-
taining 50 mM glucose at a concentration of 5 mg/ml. The resulting
solution was then incubated at 37 °C for 1 week. Prior to further
experiments, salts and sugar components were then removed from the
peptide solution by reverse phase HPLC as described above. Glycated
peptide was then isolated from non-glycated peptide for NMR and mass
spectrometric analysis using commercially available Glyco GelTM col-
umns (1-ml bed volume) from Pierce (Rockford, IL). The incubated
peptide sample from which the salt/sugar components had been re-
moved previously by reverse phase chromatography was then redis-
solved in 0.05 M HEPES (pH 8.5) and loaded onto the columns preequili-
brated in the equilibration/wash buffer provided by Pierce. The column
was then washed (5-column volumes), and the glycated peptide was
eluted (in 3-column volumes) using the procedure previously described
by Zhao et al. (19). The glycated fraction was then desalted by reverse
phase chromatography, as described above, and freeze-dried. Control,
non-glycated peptide for NMR analysis was generated by heating the
synthesized and purified peptide at 5 mg/ml for 1 week at 37 °C in PBS
(i.e. in the absence of glucose), desalted by reverse phase HPLC, and
freeze dried. Both the glycated and non-glycated HSA543–557 peptides
were then subjected to electrospray mass spectrometry (as described
above) and NMR analysis.
NMR Sample Preparation—All of the NMR samples were prepared
to a final volume of 300 l for use in a Shigemi BMS005V NMR tube by
dissolving purified, freeze-dried peptide to provide a final concentration
of 2 mM peptide in PBS at pH 6.4 (phosphate concentration 25 mM and
saline concentration of 100 mM). To this system, TFE-d3 was added as
a helix stabilizer to provide a final concentration of 30% (v/v) in the
system. TFE was used following AGADIR (20, 21) analysis of the
peptide that identified the helical propensity of the standard peptide as
0.21. Peptides with this level of propensity will only highlight regions of
helical tendency with the addition of TFE (20). 30% (v/v) TFE was
considered the lowest proportion of TFE that could be used to give rise
to a helical structure. This was confirmed from the NMR NOE contacts
observed for the standard helix. To make a meaningful comparison, all
of the Amadori modified peptide data were obtained under identical
conditions to those used for the standard peptide.
NMR Spectroscopy—All of the experiments were recorded at 10 °C on
a Varian UnityINOVA 600 MHz NMR spectrometer with a z-shielded
gradient triple resonance probe using standard procedures. For each
peptide sample, a two-dimensional nuclear Overhauser effect spectros-
copy (NOESY) and total correlation spectroscopy (TOCSY) experiments
were recorded with mixing times of 250 and 68.4 ms, respectively. These
experiments were collected with 512 and 1024 complex points with acqui-
sition times of 64 and 128 ms in the indirectly and directly acquired 1H
dimensions, respectively. The maximum theoretical NOESY enhance-
ment was estimated to be between 70 and 90% theoretical maximum,
whereas our projected ROESY enhancements were expected to be 60%.
Therefore, NOESY experiments were chosen in this analysis and vali-
dated by obtaining build-up curves that also confirmed 250ms as themost
appropriate mixing time. In addition, a two-dimensional double-quan-
tum-filtered correlated spectroscopy (DQFCOSY) experiment was col-
lected for each peptide with 1024 and 2048 complex points with acquisi-
tion times of 128 and 256 ms in the indirectly and directly acquired 1H
dimensions, respectively. Amides in slow exchange and deemed capable of
being hydrogen bond donors were identified from a NOESY experiment
that was collected with 256 and 1024 complex points with acquisition
times of 32 and 128 ms in the indirectly and directly acquired 1H dimen-
sions, respectively, obtained from a peptide sample resuspended in 2H2O.
Data processing and analysis were carried out on Sun Blade 100 and
Transtec X2100 Linux workstations using NMRPipe (22) to process and
NMRView (23) to view processed data.
Structural Calculations and Analysis—All of the structural calcula-
tions were obtained using the Crystallography and NMR System (CNS),
version 1.1 (25, 38), running on Silicon Graphics O2 and Transtec
X2100 Linux workstations. CNS parameter files were modified to in-
corporate the topology of the modified lysine residue for calculations. All
of the NOE contacts were classified into one wide classification between
1.8 and 5.0 Å with final structures calculated from extended coordinates
using the standard CNS NMR anneal protocol with the sum averaging
for dynamic annealing with NOEs from both extended and folded pre-
cursors (24). A final structural ensemble of 40 structures for each
peptide was produced with all of the structures used to produce statis-
tical energy and root mean square (r.m.s.) deviation structural infor-
mation. Backbone and heavy atom r.m.s. deviation values were ob-
tained using MOLMOL, version 2k.2 (25), on a computer running
Microsoft Windows 2000. The structural integrity of each ensemble was
evaluated using PROCHECK-NMR (26) run on a Transtec X2100 Linux
workstation. Energy comparisons between structures created from the
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NMR constraint data and the equivalent human serum albumin helix
were made using GROMOS96 43Bl parameter set (27) within DEEP-
VIEW, version 3.7 (28).
RESULTS
Peptide Synthesis, Glycation, and Purification—The peptide
sequence corresponding to HSA -helix 28 (residues 543–557)
was successfully synthesized on a Shimadzu PSSM-8 multiple
peptide synthesizer as determined by mass spectrometry (Ta-
ble I). The peptide sequence was identical to that found in the
native HSA molecule with the exception that the N-terminal
lysine residue was replaced with an arginine residue to prevent
glycation on the lysine amino side chain of this residue (Lys543).
The peptide was synthesized with the N-terminal amino group
blocked with an acetyl group to prevent potential glycation at
this site in the synthetic peptide. Following incubation with
glucose and purification of the glycated peptide from non-gly-
cated peptide using a Glyco Gel column, mass spectrometry
analysis confirmed that the peptide was glycated with one
glucose residue per peptide molecule (i.e. not di-glycated), as
indicated by an increase in the [MH] ion by 162 Da (Table I).
From these data, it was not possible to confirm whether glyca-
tion had occurred entirely at one lysine residue, preferentially
at one of the two-lysine residues in the di-lysine motif, or
whether there was an equal distribution between the two. This
was resolved during the NMR analysis (see below). We note
that it has previously been shown that the sugar moieties in
glycated human serum albumin occur as an equilibrium of the
-pyranose (59%), -furanose (19%), and -furanose (24%) ano-
mers (29). Phenylboronate purification of Amadori products
selectively binds -furanose sugar anomers; however, because
the confirmations are in rapid equilibrium, the yield of glycated
peptide is likely to be close to quantitative.
NMR Resonance Assignments—Spin systems were identified
by analysis of two-dimensional DQFCOSY and TOCSY NMR
spectra, and all of the observed 1H chemical shifts are listed in
Table II. Assignments for the majority of 1H spin systems were
possible for both the standard and Amadori-modified peptide
with the exception of amino acid Ile547 in the standard peptide.
The H shift of the N-terminal amino acid Arg543 was not
observed in either standard or modified peptide. The assign-
ment of the modified Amadori lysine was possible following the
observation of a duplicated set of resonances in the HN region
of the TOCSY spectrum for the modified lysine side chain (H,
H, H, and H). The first set of resonances are correlated from
the backbone HN of the lysine, but chemical modification trans-
forms the side chain lysine NH3
 group to a HN group (H) and
provides a second HN correlation and duplication of the lysine
side chain 1H resonances. Resonances of the Amadori peptide
were achieved from both the DQFCOSY and TOCSY data to-
gether with H protons identified by the NOESY through-space
correlation to H.
Structural Assignments and Additional Restraints—
Through-space assignments were achieved using two-dimen-
sional NOESY spectra of both standard and Amadori-modified
peptide (see Fig. 1). Amides in slow exchange and deemed capa-
ble of being hydrogen bond donors were identified from a NOESY
experiment obtained from a peptide sample resuspended in
2H2O. Additional 	 restraints were obtained from the application
of the Karplus relationship to 3JHNH that were obtained from
high resolution DQFCOSY spectra. 3JHNH values 5 Hz were
used to constrain 	 for that residue to60 30°. A cut-off value
of 5 Hz was used to allow for the fact that 3JHNH values obtained
by DQFCOSY are always larger than those obtained by more
accurate heteronuclear NMR methods (30).
With the exception of Ile547 in the standard peptide where an
NOE distribution was not observed, the NOE distribution was
uniform across all of the residues in both peptides. A total of 23
NOEs were found between the modified Lys548 and residues
Arg545, Gln546, and Ile547 that were crucial in defining the struc-
tural changes upon modification. A summary of the number of
contact types and additional restraints are shown in Table III
with the distribution of restraints across each peptide shown in
Fig. 2, a and b. NOE contact types observed in Fig. 2a for the
standard peptide support a standard helix conformation with
NOEs observed between H:i and HN:i  3 as well as H:i and
H:i  3. Additionally, slow HN exchange and 3JHNH values 5
Hz were observed for the majority of residues within the stand-
ard peptide with the exception of Ile547, as the resonances from
this residue were not observed in our system. The resonances
from Ile547 were difficult to assign because of placement of the H
resonance directly over the water resonance. This was confirmed
by observing and assigning Ile547 resonances in the absence of
TFE (data not shown). Fig. 2b highlights the NOE contact types
for the Amadori-modified peptide and defines a region from
Lys549 to Glu555 that shows similar helix NOE contacts to those
observed throughout the standard peptide. This is also confirmed
from the observed HN exchange and 3JHNH values obtained for
the modified peptide. The N-terminal region of the Amadori
peptide gave rise to reduced H:i and HN:i 3 but increased H:i
and H:i  3 together with H:i and HN:i  2 and i  3 contacts.
In this region, there was a single retarded HN exchange and no
3JHNH values 5 Hz.
Structure Calculations and Analysis—All of the structural
data were determined using CNS as described under “Experi-
mental procedures.” No calculated structure gave violations
greater than 0.2 Å or bond angle violations greater than 5° from
the restraint data when all 40 structures were used to compute
the ensemble average structural set. R.m.s. deviation statistics
over all backbone atoms for residues 544–556 for the ensemble
of 40 structures for both the standard and Amadori-modified
peptide were found to be 0.37 and 0.48 Å, respectively. The
backbone ensembles for both peptides are shown in Fig. 3, a
and b, respectively, together with the ensemble average struc-
tures and key residues shown as ribbon schematics in Fig. 3,
c–f. Corresponding r.m.s. deviations over all of the heavy atoms
for each 40-structure ensemble of the standard and Amadori-
modified peptides were found to be 1.29 and 1.45 Å, respec-
tively. PROCHECK-NMR analysis of the Ramachandran plot
for the 40-structure ensemble of the standard peptide identi-
fied that 100% of all of the residues fell in either the most
favored or additionally allowed regions of the -helix. Equiva-
lent analysis of the Amadori-modified peptide identified 84.6%
of all of the residues falling in the most favored or additionally
allowed regions with the remaining 15.4% falling into the gen-
erously allowed regions of the -helix. Ensemble average ener-
gies for each peptide are shown in Table IV together with the
equivalent energies created from helix 28 extracted directly
from the HSA x-ray structure.
TABLE I
Mass spectral characterization data of the unmodified and glycated HSA543–557 synthetic peptide
Peptide Theoretical MHa Measured MHa Theoretical M2H2a Measured M2H2a
Unmodified 1853.1 1853.2 927.1 927.5
Glycated 2015.1 2015.2 1008.1 1008.2
a Monoisotopic mass.
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DISCUSSION
Incubation of the model HSA peptide in glucose resulted in
the glycation of Lys548, as determined by NMR spectroscopy
(see below), in preference to Lys549. Although Lys-Lys se-
quences are known to be more reactive toward protein glyca-
tion due to local acid-base catalysis, it is also thought that
preferential protein glycation at one lysine residue in a di-
lysine motif is, at least partially, due to the relative accessibil-
ities of the two lysine side chains in question (2, 31). However,
the model peptide used in this study exhibited no measurable
secondary structure in aqueous PBS solution in the absence of
TFE and therefore stabilized structural aspects would not ap-
TABLE II
NMR assignment list of observed 1H chemical shifts for the standard and Amadori-modified peptide in PBS, 30% (v/v) TFE at 10 °C
All of the chemical shifts are referenced externally to 100 M solution of dimethylsilapetane sulfonic acid in PBS, 30% (v/v) TFE.
Residue HN H Others
Standard Peptide
Arg543 H2/3 1.703; H2/3 1.845; H2/3 3.220
Glu544 8.485 4.385 H2/3 2.132; H2/3 2.440
Arg545 8.261 4.235 H2/3 1.843; H2/3 1.682; H2/3 3.222
Gln546 8.981 4.182 H2/3 2.04; H2/3 2.315; H21/22 6.879/7.624
Ile547
Lys548 8.516 4.160 H2/3 1.685, 1.828; H2/3 1.438/1.516; H2/3 1.700/1.858; H2/3 2.988
Lys549 8.205 4.412 H2/3 1.663/1.865; H2/3 1.901; H2/3 1.706; H2/3 3.279
Gln550 8.416 4.306 H2/3 2.118; H2/3 2.416; H21/22 6.823/7.512
Thr551 8.129 4.269 H 4.238; H2 1.229
Ala552 8.139 4.333 H 1.446
Leu553 8.069 4.310 H2/3 1.616; H 1.677; H1/2 0.888/0.944
Val554 7.833 4.098 H 2.121; H1/2 0.961
Glu555 8.275 4.322 H2/3 1.957/2.086; H2/3 2.320
Leu556 8.154 4.416 H2/3 1.708; H 1.627; H1/2 0.889/0.943
Val557 7.518 H 2.109; H1/2 0.913
Amadori peptide
Arg543 H2/3 1.681/1.753; H2/3 1.869; H2/3 3.246
Glu544 9.062 4.145 H2/3 2.094; H2/3 2.380
Arg545 7.383 4.215 H2/3 1.686, 1.764; H2/3 1.924; H2/3 3.285
Gln546 8.411 4.269 H2/3 2.190, 2.190; H2/3 2.480; H21/22 6.784/7.413
Ile547 8.118 3.991 H 1.474; H2 1.217; H12/13 0.946; H1 0.886
Lys*548 8.275 4.213 H2/3 1.587, 1.931; H2/3 1.473; H2/3 1.772; H2/3 3.260; H 8.556; H2/3 3.260/4.173; H
2 4.678;
H2 3.290; H2 3.480; H2/3 3.444/3.528
Lys549 8.039 4.193 H2/3 1.923; H2/3 1.678, 1.772; H2/3 1.772; H2/3 3.283
Gln550 8.042 4.257 H2/3 2.181; H2/3 2.435; H21/22 6.840/7.558
Thr551 8.148 4.323 H 4.244; H2 1.281
Ala552 8.054 4.325 H 1.502
Leu553 8.012 4.305 H2/3 1.790; H 1.656; H1/2 0.945
Val554 7.778 4.089 H 2.201; H1/2 1.018
Glu555 8.114 4.383 H2/3 2.058/2.168; H2/3 2.388/2.470
Leu556 8.078 4.450 H2/3 1.688/1.790; H 1.764; H1/2 0.913/0.960
Val557 7.531 4.123 H 2.166; H1/2 0.963
FIG. 1. Fingerprint HN-HN region of
two-dimensional NOESY NMR spectra
for standard (a) and Amadori-modified (b)
peptides obtained using 250-ms mixing
periods is shown. All of the assignments
are illustrated in the format [vertical (F1)
ppm, horizontal (F2) ppm] and are for HN
unless stated. c, the chemical structure of
the glycated lysine residue.
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pear to account for the exclusive glycation of Lys548 in prefer-
ence to Lys549. Preferential glycation at Lys548 could be due to
local acid-base catalysis and the immediate neighboring amino
acids, resulting in the amino group of Lys548 being more nu-
cleophilic than that of Lys549; however, it is clear that long-
range structural affects must be involved because the adjacent
Ile547 is unlikely to affect the pKa of Lys
548. We suggest that it
is possible that, although the mean structure is random in
aqueous PBS solution, the chemical modification of Lys548 is
catalyzed when the random coil approximates the helical struc-
ture in the protein. This may occur when the side chain of
Arg545 approaches that of Lys548 and the charge on Arg545
suppresses the charge on (and lowers the pKa of) Lys
548. How-
ever, it is also likely that Glu544 may be in a position to catalyze
the Amadori rearrangement on Lys548. In this respect, it is
interesting that the position of Glu544 is significantly altered in
the glycated peptide relative to the non-glycated (standard)
peptide (see Fig. 4).
The H chemical shift differences between the standard and
modified peptide were found to be moderately small with the
exception of residues Glu544 and Lys549 as indicated in Fig. 4.
This finding suggests that similar local conformation exists
across the entirety of both peptides in accordance with known
observations of H chemical shift in the prediction of secondary
structure elements (32). Upon initial inspection, one may be
lead to believe that Lys549 is the modified peptide on the basis
of the H shift difference alone because of the large difference
in H chemical shift. We know from both NOESY and chemical
shift assignments, as outlined under “Results,” that Lys548 is
modified in the glycated peptide. This is also confirmed by
analysis of the H chemical shift values for Lys548 and Lys549 in
both the standard and modified peptide. The 1H chemical shift
difference between the standard and modified peptide for
Lys548 H is 0.272 ppm compared with 0.058 ppm observed for
Lys549. Because the H is in close proximity to the modification,
it stands to reason that the greatest shift change will be ob-
served by the H of the lysine that is modified, in this
case, Lys548.
The standard peptide in 30% (v/v) TFE folds to form an
-helical peptide structure (Fig. 3). All of the NOE contact data,
hydrogen exchange, and 3JHNH data support this observation,
and the ensemble of 40 structures provides a model whereby
100% modeled amino acids in the ensemble fall inside the
allowed regions for an -helix in a Ramachandran plot. Fig. 3,
c and e, shows a ribbon form of the ensemble average structure
that adopts a helix with key residues Arg545 and Lys548 on one
FIG. 2. Schematic of NOE contact types, hydrogen bond accep-
tors, and residues giving rise to  restraints for both the stand-
ard (a) and Amadori-modified (b) peptides.
FIG. 3. Superimposition of all backbone bonds of the 40-structure
ensemble calculated from NMR data for standard peptide (a) and Ama-
dori-modified peptide (b) is shown. c–f, ribbon diagrams created in
MOLMOL of the ensemble average structures are shown of the stand-
ard peptide (c and e) and Amadori-modified peptide (d and f). Key
residue side chains are labeled and shown as ball and stick structures.
e and f were created by 90° anti-clockwise rotation through a vertical
axis defined in c and d. d clearly shows the site of the carbohydrate
moiety attached to Lys548.
TABLE III
List of NOE, hydrogen bond, and torsion angle connectivities for both standard and Amadori-modified peptide
Standard peptide Amadori-modified peptide
NOEs Intraresidue 32 36
Sequential 74 61
i  i  2 28 24
i  i 3 76 75
i  j (	3) 22 30
Total 232 226
Retarded amide hydrogen exchange 9 5
Tortion angles 	 8 5
TABLE IV
Average ensemble energies (kJ mol1) for calculated structures
of both standard and Amadori-modified peptide obtained from
DEEPVIEW using GROMOS96
Energies for the equivalent helix within HSA structure 1AO6.pdb are
also shown for comparison.
Energy Standard Amadori Helix from HSA1AO6.pdb
Bonds 15.09 15.98 10.70
Angles 66.78 97.60 65.10
Torsions 78.01 45.40 76.20
Impropers 23.43 30.20 20.90
Nonbonded 246.76 269.73 366.79
Electrostatic 697.03 526.09 454.85
Total (kJ mol1) 760.48 606.64 648.74
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face of the helix and Gln546 rotated on the top face of the
peptide. The ribbon view highlights an exaggerated tightening
of the helix at both the N and C termini that is most probably
due to the CNS modeling. Because both terminal regions have
no additional constraints from hydrogen bonding to assist in
the calculation and modeling of the peptide helical structure,
these regions will tend to tighten slightly as observed within
the calculation. Narrower helical 	 angle constraints could
have been used at the termini to reduce this effect, but it was
considered important not to over-constrain any aspect of the
data and risk providing structural effects that could not be
explained.
NMR data of the Amadori-modified peptide in 30% (v/v) TFE
define a fold that forms a more complicated structure compared
with the standard peptide. Figs. 2b and 3, b, d, and f, show the
C-terminal region of the peptide from Gln550-Thr551 toward the
C terminus forming a standard helix that does not differ
greatly from the standard peptide helix in this region. This is
illustrated by the fact that the backbone r.m.s. deviation for
residues Gln550 and Leu556 for an 80-structure ensemble (40
standard structures and 40 Amadori-modified structures) is
only 0.25 Å. As with the standard peptide, the NOE contact
data, hydrogen exchange, and 3JHNH data support the conclu-
sion that the region from Gln550 to Leu556 is helical.
Fig. 5 shows the detailed arrangement of Arg545, Gln546,
Ile547, and the modified lysine, Lys*548, in the Amadori-modi-
fied peptide in the ensemble average model that is supported
by 23 NOE interactions between residues 545–547 and the
modified Lys*548. Ile547 HN and H have contacts to Lys*548 HN,
H, and H. Gln546 has NOE contacts from its side chain atoms
Hand H to Lys*548 H, H, H, and H as well as the modifi-
cation protons H and H. Arg545 has NOE contacts from its
side chain atoms H, H, and H to protons H
, H, H, and H
in the Amadori structure that can be seen clearly associated as
a contact core in Fig. 5. This overall appearance is observed in
all 40 structures of the ensemble with the modified carbohy-
drate chain on the lysine parallel to the side chain of Arg545.
This is confirmed in a quantitative manner by calculation of an
r.m.s. deviation of 0.36 Å for all of the side chain carbon atoms
from both Arg545 and Lys*548 over the 40-structure ensemble of
FIG. 4. Difference in 1H NMR
chemical shift observed for each res-
idue in the standard and Amadori-
modified peptide.
FIG. 5. Ball and stick detail of interacting side chains Arg545,
Gln546, Ile567, and the modified lysine, Lys*548, in the Amadori-
modified peptide.
FIG. 6. a and b, ribbon diagram of HSA showing the N-terminal
region of helix 28 and adjacent electrostatic contact via Lys543
to Asp207 in helix 10.
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the modified peptide. It is likely that the interaction is stabi-
lized by hydrogen bonding between protons on the Arg545 H
groups and hydroxyl oxygen atoms attached to C of the mod-
ified Lys*548. This arrangement would also be stabilized by an
electrostatic attraction between Arg545 side chain NH2 groups
and electronegative oxygen atoms attached to both C and C
atoms in the modification. This association and contact be-
tween the modified glycated chain on Lys*548 and Arg545 twists
the C-terminal region of the helix that is observed in the
standard peptide. Interestingly, there still appears to be some
helical character to this region as seen from the presence of
H:i and H:i  3 NOE contacts, which in this region appear
more prevalent than HN:i and H:i  3 contacts. This finding
suggests that this region adopts a conformation more in line
with a 310 helix as H
:i and H:i to HN:i  2/:i  3 are stronger
in such systems (33).
Despite the suggestion of the model that the Amadori mod-
ification places structural strain on the peptide, PROCHECK
analysis for the ensemble of 40 structures showed that 84.6% of
the modeled amino acids resided inside the favored allowed
regions for -helix in a Ramachandran plot. It would appear
that there is strain in 	/
 for Gln546 and Ile547 and that this is
created by the interaction of the Amadori Lys*548 side chain
with Arg545 because the 15.4% that fell inside generously al-
lowed regions consisted entirely of 	/
 distributions from
Gln546 and Ile547. These two residues (Gln546 and Ile547), to-
gether with Arg545, provided virtually all of interactions with
the modified Lys548 Amadori side chain.
An analysis of the Protein Data Bank coordinates for HSA
shows that, in the intact protein structure, two disulfide bonds
exist between Cys538-Cys583 and Cys582-Cys591 that hold heli-
ces 28, 29, and 30 together. This stabilization is further sup-
ported by an electrostatic attraction between the side chains of
Arg545 and Glu580. However, unlike much of the HSA structure,
helices 28–30 at the C terminus are not attached to the bulk of
the protein by a disulfide bond (only to each other) but are held
relative to the bulk structure via a salt bridge created between
the side chains of Lys543 of helix 28 and Asp207 in helix 10. This
salt-bridge arrangement is depicted in Fig. 6. Close analysis of
the modified structures shown in Fig. 3, e and f, confirmed an
anticlockwise 90° twist in the orientation of the N terminus of
the peptide upon modification that would remove the correct
orientation of Lys543 with respect to its salt bridge with Asp207
in the intact protein. If disruption of this salt bridge was to
occur in the intact protein, this would result in helices 28–30
becoming more flexible and mobile, loosening the protein struc-
ture, exposing hydrophobic residues, and increasing the sus-
ceptibility of the three helices to hydrolysis and cleavage from
the structure. The reorientation of residues 543–548 would also
remove the electrostatic interaction between Glu580 and Arg545
and destabilize the turn regions of helices 28–30. Previous
NMR investigations on proteins with disulfide bonds have
shown degrees of conformational flexibility around these
bonds (34, 35), and any loss of nearby electrostatic stabiliza-
tion will increase the conformational flexibility in the region
around the disulfide bond, in this case around Cys538 and
Cys583. This would further destabilize the structure in this
region of HSA.
We have clearly shown that glycation of a model peptide
system can result in disruption of local secondary structure and
alter helicity as suggested by Sell and Monnier (11). To our
knowledge, this is the first example that definitively shows
that glycation can influence and change secondary structural
elements. Although we have not determined this change in
helical structure in the intact HSA protein molecule upon gly-
cation of Lys548, we predict that the few interactions holding
this part of the molecule together are likely to be disrupted by
such a modification. This prediction disagrees with a previous
study by Coussons et al. (36) who concluded that glycation had
minimal effects on the folded structure of HSA; however, this
observation was based on far-UV circular dichroism (CD) meas-
urements, which will only detect gross changes in the second-
ary structure. The disruptions described and predicted here are
unlikely to have been detected by far-UV CD. Furthermore,
helix 28 is in the region of drug-binding site 2 in HSA and
previous investigations have suggested that modification with
methylglyoxal of an arginine residue in close proximity to Ile547
modifies the ligand binding and enzymatic activity of HSA
domain 3A (37). Therefore, we suggest that glycation of Lys548
is also likely to change the ligand binding and enzymatic ac-
tivity of this domain of HSA.
A similar disruption of secondary structure in other proteins
could potentially affect protein function by, for example, chang-
ing enzymic activity, binding affinities, or exposing hydrophobic
patches leading to protein aggregation. In this way, protein gly-
cation and the formation of an Amadori product may be involved
in accelerating protein aggregation even before the formation of
AGE cross-links, which accumulate much more slowly. As such,
the formation of an Amadori product alone could be envisaged as
playing a role in pathologies such as those seen in transmissible
neurodegenerative diseases characterized by the accumulation of
an abnormally folded prion protein whereby post-translational
glycation is known to occur (8).
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